Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Molecular profiling—ready for clinical routine

Molecular profiling—ready for clinical routine editorial memo (2020) 13:365–366 https://doi.org/10.1007/s12254-020-00663-4 Molecular profiling—ready for clinical routine Armin Gerger © Springer-Verlag GmbH Austria, part of Springer Nature 2020 In this special issue of the Magazine of European Med- complexity and heterogeneity of tumors and recently, ical Oncology (MEMO) multidisciplinary experts sum- circulating cell-free DNA (cfDNA), which contains cir- marize and discuss recent developments and future culating-tumor DNA (ctDNA) in patients with cancer, perspectives of comprehensive molecular profiling has been shown to provide an accurate snapshot of spanning from specific cancer entities to agnostic a patient’s tumor, enabling the detection of tumor approaches [1–3]. subclones from metastatic lesions [6]. Although stud- The development of next-generation molecular ies have begun to prospectively use ctDNA to funnel profiling methods has enhanced our ability to inter- patients into phase I clinical trials, such trials have rogate multiple cancer-associated genomic changes only recently been initiated and only preliminary within an individual patient’s tumor. As a result of outcomes have been reported yet. such advancements, an increasing number of molec- However, a number of significant challenges are to ular aberrations have now been rendered actionable be considered with regards to next-generation molec- targets and raise hope of obtaining meaningful and ular profiling. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Molecular profiling—ready for clinical routine

memo - Magazine of European Medical Oncology , Volume 13 (4): 2 – Dec 1, 2020

Loading next page...
 
/lp/springer-journals/molecular-profiling-ready-for-clinical-routine-KnFdRwCxTG
Publisher
Springer Journals
Copyright
2020 Springer-Verlag GmbH Austria, part of Springer Nature
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-020-00663-4
Publisher site
See Article on Publisher Site

Abstract

editorial memo (2020) 13:365–366 https://doi.org/10.1007/s12254-020-00663-4 Molecular profiling—ready for clinical routine Armin Gerger © Springer-Verlag GmbH Austria, part of Springer Nature 2020 In this special issue of the Magazine of European Med- complexity and heterogeneity of tumors and recently, ical Oncology (MEMO) multidisciplinary experts sum- circulating cell-free DNA (cfDNA), which contains cir- marize and discuss recent developments and future culating-tumor DNA (ctDNA) in patients with cancer, perspectives of comprehensive molecular profiling has been shown to provide an accurate snapshot of spanning from specific cancer entities to agnostic a patient’s tumor, enabling the detection of tumor approaches [1–3]. subclones from metastatic lesions [6]. Although stud- The development of next-generation molecular ies have begun to prospectively use ctDNA to funnel profiling methods has enhanced our ability to inter- patients into phase I clinical trials, such trials have rogate multiple cancer-associated genomic changes only recently been initiated and only preliminary within an individual patient’s tumor. As a result of outcomes have been reported yet. such advancements, an increasing number of molec- However, a number of significant challenges are to ular aberrations have now been rendered actionable be considered with regards to next-generation molec- targets and raise hope of obtaining meaningful and ular profiling.

Journal

memo - Magazine of European Medical OncologySpringer Journals

Published: Dec 1, 2020

Keywords: oncology; medicine/public health, general

References